Valneva’s High-Stakes Gamble: A Single Vaccine Holds the Key

The fate of Valneva, along with millions in investor capital, hinges on critical developments unfolding in the coming weeks. Behind the scenes at this French biotech firm, a billion-dollar wager rests on the success of one pivotal vaccine candidate. With the company’s stock already under significant strain, the countdown is on: decisive clinical trial data for the Lyme disease vaccine VLA15 is anticipated before the end of 2025. The question for the market is whether this pipeline contender can reverse the company’s fortunes or if shareholders are facing another severe setback.

Investor anxiety is palpable, fueled by a recent regulatory blow. In August, the U.S. Food and Read more...